Lonigutamab
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs) . Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye diseases[1][2].
Product Specifications
CAS Number
[2362015-67-4]
Product Name Alternative
Hz208F2-4
UNSPSC
12352203
Target
ADC Antibody; Apoptosis; IGF-1R
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/lonigutamab.html
Purity
95.00
Solubility
H2O
Smiles
[Lonigutamab]
Molecular Weight
(145.12 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PE-Linked Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
PE-Linked Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
PE-Linked Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
PE-Linked Polyclonal Antibody to Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)